FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a research note published on Tuesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on the company. HC Wainwright upgraded FibroGen to a “strong-buy” rating in a research report on Tuesday, December 17th. William Blair reiterated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Trading Up 3.9 %

FGEN stock opened at $0.50 on Tuesday. The company has a market capitalization of $50.24 million, a P/E ratio of -0.41 and a beta of 0.82. The business has a 50 day simple moving average of $0.36 and a 200-day simple moving average of $0.55. FibroGen has a twelve month low of $0.18 and a twelve month high of $2.93.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.21. The business had revenue of $46.33 million for the quarter, compared to analyst estimates of $34.00 million. During the same quarter in the prior year, the company earned ($0.52) EPS. Research analysts predict that FibroGen will post -0.86 EPS for the current fiscal year.

Institutional Trading of FibroGen

A number of institutional investors have recently modified their holdings of FGEN. Point72 DIFC Ltd raised its stake in shares of FibroGen by 734.2% during the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 45,990 shares during the last quarter. Doheny Asset Management CA purchased a new position in shares of FibroGen in the 2nd quarter worth $48,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in FibroGen during the second quarter worth approximately $130,000. Sei Investments Co. boosted its position in shares of FibroGen by 38.4% in the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 41,442 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in FibroGen during the 2nd quarter valued at $145,000. 72.71% of the stock is currently owned by hedge funds and other institutional investors.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.